Please assess the completion status of the following clinical trial:

Trial Title: Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed post-transplant lymphoproliferative disease (PTLD)~  * Presents with 1 of the following:~    * Fulminant PTLD (F-PTLD)~      * Fever greater than 38°C~     * Hypotensive (for age)~     * Evidence of multiple organ involvement/failure, including at least 2 of the following:~        * Marrow (including pancytopenia without detectable B-cell proliferation)~       * Liver (coagulopathy, transaminitis, and/or hyperbilirubinemia)~       * Lungs (interstitial pneumonitis with or without pleural effusions)~       * Gastrointestinal tract hemorrhage~   * Non-fulminant PTLD (NF-PTLD)~      * Does not meet the above F-PTLD criteria~     * Considered medically refractory to reduced immune suppression (50% or more reduction of immunosuppression) for at least 1 week~* CD20 positive AND Epstein-Barr virus positive~* Must have received prior solid organ transplantation~* Must have residual disease after biopsy and/or surgery~* No PTLD central nervous system (CNS) disease, defined as positive cytology and/or radiographic evidence~PATIENT CHARACTERISTICS:~Age~* Under 31~Performance status~* Not specified~Life expectancy~* NF-PTLD patients:~  * At least 8 weeks~Hematopoietic~* See Disease Characteristics~Hepatic~* See Disease Characteristics~Renal~* Not specified~Pulmonary~* See Disease Characteristics~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* HIV negative~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 1 month since prior rituximab~Chemotherapy~* More than 4 weeks since prior chemotherapy and recovered~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* See Disease Characteristics

- Gender: ALL
- Minimum Age: None
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide, prednisone, rituximab (Type: EXPERIMENTAL): Patients receive cyclophosphamide IV over 30-60 minutes on day 1 and oral prednisone or methylprednisolone IV twice daily on days 1-5. During courses 1 and 2 only, patients also receive rituximab IV over 2-5 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression, a new primary or secondary malignancy, or unrelated disease

Based on this trial design, predict the completion outcome and termination type (if applicable).